Filter
195
Filtered Results: 195
Text search:
pericarditis
Featured
Recommendations
29
New Publications
37
Language
Document type
No document type
100
Guidelines
66
Manuals
11
Fact sheets
5
Training Material
4
Studies & Reports
4
Strategic & Response Plan
4
Resource Platforms
1
Countries / Regions
Argentina
14
India
13
Brazil
11
Kenya
8
Indonesia
8
Nepal
5
Colombia
5
Paraguay
5
Germany
4
Western and Central Europe
4
Mozambique
3
Africa
3
Cambodia
3
Latin America and the Carribbean
3
Bangladesh
3
South Africa
3
Ecuador
3
Lesotho
2
Rwanda
2
Nigeria
2
Peru
2
Venezuela
2
Bolivia
2
Uganda
2
Eastern Europe
2
Tajikistan
1
Switzerland
1
El Salvador
1
Gambia
1
Fiji
1
Malawi
1
Philippines
1
Global
1
USA
1
Dominican Republic
1
Tanzania
1
Congo, Democratic Republic of
1
Papua New Guinea
1
Russia
1
Namibia
1
Botswana
1
Zambia
1
Myanmar / Burma
1
Authors & Publishers
Publication Years
Category
Guidelines
53
Policies & Guidelines HIV & TB
41
COVID-19
32
TB
11
Women & Child Health
6
Policies
5
NTDs & Others
5
Pediatrics
4
Drugs & Medical Equipment
4
Dermatology
3
Clinical Guidelines
3
Studies & Reports
3
Capacity Building
3
Surgery & Anaesthesia
3
Communicable Diseases
3
Dental & Eye Care
2
Paediatrics
2
Diabetes
2
Vaccine-preventable Diseases
2
Gynaecology & Obstetrics
2
HIV & STI
2
Disease Prevention & Control
2
Hepatitis
1
Under-5 nutrition
1
MPOX - Monkeypox
1
Countries
1
Chagas
1
NCD
1
Cardiovascular Diseases
1
Community Health
1
Information, Education and Communication (IEC)
1
Statistics
1
Immunization
1
General Guidelines
1
Toolboxes
Country specific documents
26
Adults
9
Biontech/Pfizer Comirnaty
8
Paediatrics
7
Immunization Guidelines
7
Children
5
Clinical Guidelines
5
Long COVID/ Post-COVID Syndrome
5
Moderna
5
Training
5
Children & Adolescents
4
Detection & Diagnosis
4
Treatment & Prevention
3
Stroke
3
Public Health
3
Booster Doses
3
HIV &TB
3
Argentina
3
Chikungunya Prevention & Control
3
Meningitis Prevention & Control
2
Moldova
2
Clinical Aspects
2
COVID-19
2
Communication Material
2
COVID-19 Vaccination
2
COVID-19 Vaccination Information
2
Inactivated COVID-19 Vaccines
2
Handbooks & Manuals
2
Latin America
2
Germany
2
HIV and coinfection
2
South-east Asia Region
2
TB
2
Kenya
2
Policies & Strategies
1
Clinical Aspects, Treatment & Prevention
1
Policies & Strategies
1
Prevention & Control
1
Vaccination
1
Clinical Guidelines
1
Pediatrics
1
South Africa
1
Prevention Guidelines
1
Namibia
1
TB & Other Vulnerable Populations
1
Health & Refugee
1
Clinical aspects
1
Country Guidelines
1
Medical professionals
1
Communication & Training
1
Topics
1
General
1
Clinical Guidelines
1
General
1
For Parents & Children
1
Scientific & Research Studies
1
Vaccination & Strategy
1
Long-term Care Facilities
1
TB/HIV
1
Logistics & Supply
1
mRna Vaccines general
1
Vaxzevria (Astra Zeneca)
1
Johnson & Johnson
1
Others
1
Others
1
Community Health Workers CHW
1
Colombia
1
Brazil
1
Peru
1
El Salvador
1
Other Countries
1
Essential Medicines & Devices Lists
1
Reports & Studies
1
Infectious Diseases
1
MPOX - Monkeypox
1
Clinical Aspects & Diagnostics
1
Clinical Aspects & Diagnostics
1
Clinical Aspects & Diagnostics
1
NTDs General
1
Health Worker
1
Romania
1
Botswana
1
Drug resistant TB
1
Neurological Disorders
1
Community Worker
1
Malawi
1
TB & Prisoners
1
Disease Prevention & Control
1
Prophylactic Treatment
1
Tuberculosis
1
Lesotho
1
Uganda
1
Latin America & the Carribean
1
TB/HIV Coinfection
1
Tajikistan
1
Chikungunya
1
This diagnostic and treatment manual is designed for use by medical professionals involved in curative care at the dispensary and hospital levels. We have tried to respond in the simplest and most practical way possible to the questions and problems faced by field medical staff, using the accumulate...
Accessed November 2017
Accessed: 08.10.2019
Based on the National Guidelines for the Management of Tuberculosis in Children 2013, Department of Health, South Africa.
This document contains: The systematic reviews and GRADE assessments used at the Index-TB Guideline Panel in July 2015; The Evidence to Decision tables that record the Panel’s assessment and recommendations from
this meeting
Guía clínica y terapéutica (MSF)
recommended
Esta guía va dirigida a los profesionales de la salud que proporcionan asistencia curativa en dispensarios y hospitales. Hemos intentado responder a las preguntas y problemas con los que se enfrenta el personal sanitario, procurando dar soluciones prácticas y aunando la experiencia adquirida por M...
As of 15 May 2020, more than 4 million confirmed cases of COVID-19, including more than 285,000 deaths have been reported to WHO. The risk of severe disease and death has been highest in older people and in persons with underlying noncommunicable diseases (NCDs), such as hypertension, cardiac diseas...
Global COVID-19 Clinical Platform: Case Record Form for suspected cases of Multisystem inflammatory syndrome (MIS) in children and adolescents temporally related to COVID-19
Plataforma clínica mundial de la COVID-19. Formulario de notificación de casos presuntos de síndrome inflamatorio multisistémico (SIM) en niños y adolescentes que coincide cronológicamente con la COVID-19
Existen notificaciones de eventos relacionados con la vacuna (ESAVI) de
miocarditis/pericarditis en adolescentes tras la administración de vacunas ARNm(Pfizer y Moderna) especialmente tras la segunda dosis. Al momento no seencuentra asociación entre la enfermedad y la administración de la vacuna...
Guidelines for the care of children and adolescents diagnosed with COVID - 19.
La miocarditis es una enfermedad inflamatoria con compromiso focal o difuso del miocardio, que se presenta de forma fulminante, pudiendo ser aguda, subaguda o crónica.Las que poseen un nivel de gravedad suficiente para reconocerlas clínicamente, son raras, pero la prevalencia de los casos leves y ...
Campaña Nacional de Vacunación contra la COVID-19
La dosis de refuerzo está indicada una vez transcurridos los 4 meses (120 días) de la última dosis del esquema inicial y será con vacuna de plataforma ARNm: Pfizer-BioNTech pediátrica a partir de los 5 años o Moderna para uso pediátrico a partir de los 6 años.
La evidencia disponible a nivel internacional sobre el uso de un segundo refuerzo muestra una mayor duración de la respuesta inmune y una disminución de la internación y la mortalidad por COVID 19 en la población de adultos mayores y huéspedes inmunocomprometidos. Por otra parte, el personal de...
Los datos preliminares de eficacia se infirieron mediante un enfoque de “inmunogenicidad puente”, en el que los títulos neutralizantes obtenidos después de la vacuna en niños y niñas de 5 a 11 años se compararon con los títulos obtenidos en adolescentes de 16 a 25 años (en quienes se hab...
El siguiente manual se continuará actualizando, de ser necesario, a medida que se disponga de nueva información.
